Combining the Passeo-18 Lux Drug-Coated Balloon and the Pulsar-18 Bare Metal Stent: 12- and 24-Month Outcomes of the BIOLUX 4EVER Investigator-Initiated Trial.
Koen DelooseMarc BosiersPatrick PeetersJürgen VerbistLieven MaeneRoel BeelenKoen KeirseJeroen M H HendriksPatrick LauwersJeroen WautersMerel VerschuerenPublished in: Journal of endovascular therapy : an official journal of the International Society of Endovascular Specialists (2020)
The combination of a Passeo-18 Lux DCB followed by a Pulsar-18 stent implantation produced safe and effective outcomes in the treatment of femoropopliteal lesions at up to 24 months. Adding paclitaxel to the bare nitinol stent platform by predilating with a Passeo-18 Lux DCB seems to increase efficacy at 1 and 2 years compared with the use of bare metal stents only, which were investigated in the precursor 4-EVER study.